Please assess the completion status of the following clinical trial:

Trial Title: A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infection, as documented by any licensed ELISA test kit, and confirmed by Western blot, positive HIV-1 blood culture, positive HIV serum antigen, or plasma viremia at any time prior to study entry. If no record exists, testing must occur at screening.~2. Male or female, age 18 to 75 years of age.~3. Able to sign the informed consent, and is willing to comply with the requirements of this clinical trial.~4. Available for at least 96 weeks of follow up.~5. Males: deemed a candidate for antiretroviral therapy per referring primary care provider. (If patient is self referred, CD4 cell count must be \<400 cells/mm3 and viral load\>5,000c/ml) Females: CD4 cell count must be less than 250 cells/mm3 and viral load \>5,000 c/mL at time of enrollment.~6. If female and of child bearing potential must consent to using at least two forms of contraception.~7. Participants will be treatment naive as no prior antiretroviral therapy or antiretroviral therapy for less than 7 days in the past.~Exclusion Criteria:~1. Evidence of mutation associated with primary drug resistance to Nevirapine (K103N, Y181C, Y188L, G190S), Tenofovir (M41L, T69 insertion, Q151M, L210W,and K65R), and/or FTC (184V) previously documented, or at time of screening.~2. Patients with any of the following laboratory parameters at the screening visit: estimated creatinine clearance of \<60 ml/min; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 times the upper limits of normal; total bilirubin \>1.5 mg/dL.~3. Women with CD4 cell count \> 250 cells/ mm3 at time of entry or in males with a CD4 cell count less than 400/mm3, along with a viral load greater than 5,000c/ml. for both males and females.~4. Pregnant women or women who are breast feeding.~5. Unwillingness to use effective barrier contraception.~6. Patients with current alcohol abuse or illicit drug use that in the opinion of the Principal Investigator may interfere with the patient's ability to comply with the protocol requirements.~7. Patients with malabsorption or severe chronic diarrhea for more than 30 days.~8. Current treatment for malignancy other than basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~9. History of any chronic illness or other condition that in the opinion of the investigator would interfere with the conduct or completion of the study.~10. Patient who is, in the opinion of the investigator, unable to complete the 96-week dosing period and protocol evaluations and assessments.~11. Experimental vaccines, to include HIV vaccines.~12. Patient who is currently enrolled in an experimental protocol, or is receiving an experimental medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nevirapine, FTC, Tenofovir (Type: EXPERIMENTAL): Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete